Skip to main content
Premium Trial:

Request an Annual Quote

I Want My DNA!

Writing in the New Scientist, Daniel MacArthur and Caroline Wright say that when it comes to DTC genetic testing, they "believe that regulation is needed, but are worried that it will focus too heavily on 'protecting' consumers from their own genomes." The authors note that once "lauded" as Time's invention of the year, personal genome scans have had a hard time "living up to that promise," and consequently their medical value has been limited. But, MacArthur and Wright say, not all DTC companies hold themselves to the same standards. "What is needed is measured regulation that protects unwary consumers, punishes false claims and weeds out fraudsters without destroying the potential of DTC genetics to drive innovation and educate the public," they write.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.